Angela Packingham
Primary Care · Albuquerque, NMNPI 1477229193
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Otsuka Pharmaceutical Development & Commercialization, Inc. at 25.6% of the total.
Across 11 payments — averaging $38.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$108
- Acadia Pharmaceuticals Inc$93
- Ultragenyx Pharmaceutical Inc.$64
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$50
- Novartis$42
- Amarin Pharma, Inc.$26
- plus $40 from 3 others
What the payments were for
- Food & beverage$424100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $108 |
| Acadia Pharmaceuticals Inc | 1 | $93 |
| Ultragenyx Pharmaceutical Inc. | 1 | $64 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $50 |
| Novartis | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $26 |
| Pfizer | 1 | $15 |
| Lilly USA, LLC | 1 | $13 |
| AstraZeneca | 1 | $12 |
How this compares
$424 in reported general payments places this provider in the 65th percentile of 58 primary care providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 22 | $525 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $326 |
| Duloxetine Hcl | 12 | $310 |
| Atorvastatin Calcium | 23 | $240 |
| Lisinopril | 17 | $239 |
| Amlodipine Besylate | 13 | $178 |
| Alendronate Sodium | 13 | $129 |
| Levothyroxine Sodium | 13 | $120 |
| Metformin Hcl | 12 | $60 |
Paid to pharmacies, not to this prescriber.
Other primary care in Albuquerque
- Bianca MezaAlbuquerque$59K
- Melissa PinoAlbuquerque$4K
- Jacqueline MessierAlbuquerque$3K
- Christine MayesAlbuquerque$2K
- Rachel VanwetteringAlbuquerque$2K
- Catherine JamesAlbuquerque$2K
- Koryn MichaudAlbuquerque$1K
- Christie DommeAlbuquerque$1K
- Pala Nicole RiveraAlbuquerque$905
- Nena VigilAlbuquerque$595
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.